pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY
Harmony Biosciences Holdings
Harmony Biosciences Holdings clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
- Founded
- 2017
- Employees
- 332
- Programs
- 21
- Drugs
- 14
- Patents
- 6
Harmony Biosciences Holdings projects
10 ClinicalTrials.gov programs sponsored by Harmony Biosciences Holdings.
Harmony Biosciences Holdings has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Clemizole HCl
Harmony Biosciences Holdings
Dravet Syndrome
1 trial -
Clemizole HCl
Harmony Biosciences Holdings
Lennox Gastaut Syndrome
1 trial -
HBS-101-CL-312
Harmony Biosciences Holdings
Prader-Willi syndrome
1 trial -
HBS-301 tablet
Harmony Biosciences Holdings
Idiopathic Hypersomnia
1 trial -
Open-label pitolisant
Harmony Biosciences Holdings
Idiopathic Hypersomnia
1 trial -
Pitolisant
Harmony Biosciences Holdings
Idiopathic Hypersomnia
1 trial -
Pitolisant
Harmony Biosciences Holdings
Prader-Willi Syndrome
1 trial -
Pitolisant tablet
Harmony Biosciences Holdings
Prader-Willi Syndrome
1 trial -
ZYN002 Transdermal Gel Cannabidiol (CBD)
Harmony Biosciences Holdings
Fragile X Syndrome (FXS)
1 trial -
ZYN2-CL-033
Harmony Biosciences Holdings
Fragile X syndrome (FXS)
1 trial
Frequently asked questions
How many clinical projects does Harmony Biosciences Holdings have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.